Viatris finance interviews test whether candidates understand how financial management at a complex generics and off-patent pharmaceutical company differs from branded pharma or industrial company finance – where gross-to-net deductions including Medicaid best price rebates, PBM rebates, distributor chargebacks, and 340B ceiling price obligations can reduce gross revenue by 50-70% to determine net revenue figures that require finance to model separately from WAC-based revenue projections, where the November 2020 Mylan-Upjohn combination required purchase price allocation across acquired product intangibles, customer relationships, and manufacturing assets whose amortization schedules create ongoing non-cash charges that must be excluded from adjusted earnings presentations to understand the business's underlying operating performance, and where Viatris's significant post-combination debt load requires finance to manage leverage ratios and interest coverage metrics against the deleveraging commitments that rating agencies and debt covenant compliance require. Finance at Viatris spans gross-to-net revenue management and deduction forecasting (where accurate net revenue forecasting requires tracking Medicaid best price and average manufacturer price calculations that determine quarterly Medicaid rebate obligations, modeling PBM rebate liabilities by product and formulary tier as contract terms change, and estimating distributor chargeback experience as pharmacy-level sales mix shifts between contract and non-contract accounts), Upjohn-Mylan acquisition integration financial accounting (where the combination's purchase price allocation created amortizable intangible assets including acquired product rights, customer relationships, and trade names with varying useful lives, and where goodwill impairment testing for Viatris's reporting units requires assessing whether acquisition economics remain supported by current commercial performance), debt management and deleveraging economics (where Viatris's approximately $14 billion in gross debt at combination close represented a leverage ratio that management committed to reducing through cash generation and asset monetization including the biosimilar business divestiture to Biocon Biologics completed in November 2022 that generated proceeds against debt reduction), and ANDA lifecycle financial modeling (where first-to-file generic product launch economics require modeling the 180-day exclusivity period revenue, the post-exclusivity price erosion curve as additional generic manufacturers enter, and the cumulative NPV of a generic product investment against the ANDA development cost and litigation settlement payments that the patent challenge strategy requires).

Start your free Viatris Finance practice session.

What interviewers actually evaluate

Gross-to-Net Economics, Acquisition Accounting, and Generic Product Financial Modeling

Viatris finance interviews probe whether candidates understand how pharmaceutical financial management differs from industrial or consumer company finance in the gross-to-net complexity (pharmaceutical revenue recognition requires tracking multiple mandatory and contractual deductions from WAC that determine the net revenue that actually flows to the business – where the Medicaid best price calculation requires comparing every commercial price and discount offered to any customer against the resulting Medicaid net price obligation, where PBM rebate obligations are not recorded until the quarter of sale based on utilization reports received weeks after the payment is due, and where the chargeback reconciliation process for distributor customers requires matching pharmacy-level sales records against contract eligibility to determine the per-unit refund owed to distributors who sold below WAC to qualified contract customers), the ANDA product financial modeling sophistication (generic product financial analysis requires modeling the pre-exclusivity competitive landscape, the revenue concentration during the exclusivity window before other manufacturers enter, and the price erosion trajectory as the market approaches commodity pricing with multiple approved generic manufacturers – where the NPV of a generic product launch investment is highly sensitive to the exclusivity period assumption and the number of generic competitors who receive approval in the first 18 months post-launch), and the post-combination debt management priority (Viatris's commitment to deleveraging from the high leverage ratio at combination close requires finance to optimize free cash flow generation, prioritize capital allocation toward debt reduction over growth investment when leverage remains above target ratios, and evaluate asset monetization opportunities like the Biocon biosimilar divestiture against the revenue and earnings trade-offs of removing a growing business from the consolidated results).

The foreign exchange management complexity creates significant financial modeling requirements: Viatris generates revenue in approximately 165 countries across all major global currencies, and the translation of international revenue into US dollar reported results creates earnings volatility from currency movements that finance must communicate to investors as separate from operational performance trends – where a strengthening US dollar reduces the reported value of strong underlying performance in European or emerging market operations.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
Gross-to-net deduction modeling and Medicaid best price analysis Do you understand how to build Viatris's net revenue model for a branded pharmaceutical product – how to calculate the Medicaid average manufacturer price for a product and model the resulting best price Medicaid rebate obligation as the minimum percentage of AMP that must be rebated to state Medicaid programs, how PBM rebate contracts affect the net revenue per unit for products on Tier 2 versus Tier 3 formulary positions, and how to assess the net revenue impact of a new commercial contract that offers a deeper rebate to a large PBM in exchange for preferred formulary placement when the commercial rebate may lower the product's effective net price in ways that reset the Medicaid best price obligation across all Medicaid units? We flag finance answers that reference gross-to-net without engaging with the Medicaid best price calculation mechanics and PBM contract revenue modeling that determine actual pharmaceutical net revenue. AMP and best price calculation, PBM rebate net revenue modeling, commercial contract Medicaid best price impact
Acquisition purchase price allocation and intangible amortization management Can you describe how the Mylan-Upjohn combination's purchase price allocation affected Viatris's post-combination financial statements – what the major intangible asset categories were that were identified in the purchase price allocation including product rights, customer relationships, and trade names, how the amortization schedules for acquired intangibles create non-cash charges that reduce reported GAAP earnings relative to adjusted or core earnings measures, and how to construct the adjusted earnings reconciliation that allows investors to evaluate Viatris's operational performance excluding the purchase price amortization that is not representative of ongoing cash earnings power? We score whether your acquisition accounting analysis engages with the specific intangible asset categories in pharmaceutical purchase price allocations and the adjusted earnings presentation that pharma companies use to communicate performance excluding acquisition-related amortization. Pharmaceutical intangible asset category identification, PPA amortization schedule, adjusted earnings reconciliation
Debt management and deleveraging free cash flow prioritization Do you understand how to manage Viatris's balance sheet deleveraging from the approximately $14 billion gross debt position at combination close – how to develop the free cash flow model that estimates the annual cash available for debt reduction after capital expenditures, working capital investment, and dividend obligations, what the asset monetization options are for accelerating deleveraging including portfolio divestitures like the Biocon biosimilar transaction and Medicaid rebate receivable factoring, and how to communicate the deleveraging timeline to credit rating agencies and debt capital markets investors who require confidence that Viatris is committed to reducing leverage to investment-grade ratios within a credible timeframe? We detect finance answers that describe pharmaceutical debt management as general balance sheet optimization without engaging with the free cash flow generation and asset monetization strategy specific to a post-combination pharmaceutical company managing to a deleveraging commitment. Free cash flow available for debt reduction modeling, asset monetization option evaluation, rating agency deleveraging communication
Generic product launch financial modeling and exclusivity economics Can you describe how to build the financial model for a generic pharmaceutical product launch – how to estimate revenue during the 180-day exclusivity period when Viatris may be the only generic manufacturer or one of limited approved generics versus post-exclusivity revenue when commodity pricing reflects the full competitive market, how to model the capital investment decision for at-risk launch before patent litigation is resolved including the contingent liability from potential patent infringement damages if the patent is upheld, and how to calculate the NPV of the full ANDA investment including development costs, litigation settlement payments, and at-risk launch inventory investment against the expected exclusivity period revenue and post-exclusivity tail? We flag finance answers that treat generic product launch as a standard product launch NPV without engaging with the patent litigation contingency and exclusivity window economics that make generic pharmaceutical investment analysis distinct from other pharmaceutical product financial modeling. Exclusivity period revenue estimation, at-risk launch contingent liability, full ANDA investment NPV

How a session works

Step 1: Choose a Viatris finance scenario – gross-to-net revenue modeling and Medicaid best price analysis, acquisition purchase price allocation and adjusted earnings management, post-combination debt management and deleveraging economics, or generic product launch financial modeling and exclusivity window analysis.

Step 2: The AI interviewer asks realistic Viatris-style questions: how you would build the quarterly net revenue forecast for EpiPen – including the gross-to-net deduction model that projects Medicaid rebate obligations based on the current AMP trend, PBM rebate accruals by formulary tier across Viatris's contracted PBM relationships, and distributor chargeback experience rates as pharmacy dispensing mix shifts between contract and non-contract accounts – and how you would explain a $45 million shortfall in EpiPen net revenue versus the prior quarter's forecast when gross revenues are tracking to plan; how you would evaluate Viatris's decision to launch at risk before the court's final patent ruling on the paragraph IV challenge for a generic product where the innovator's compound patent expires in 24 months and the at-risk launch would capture 6 months of effective exclusivity ahead of the patent expiration date – including how to quantify the upside of 6 months of exclusivity-period revenue against the contingent infringement damages exposure if the patent is upheld, what the probability-adjusted NPV is at different probability assessments for the court ruling, and what financial protections Viatris should establish before proceeding with at-risk launch; or how you would structure the investor presentation for Viatris's annual investor day that communicates the adjusted earnings per share for the current year, the GAAP to non-GAAP reconciliation that explains the impact of Upjohn-Mylan combination amortization and restructuring charges, and the 2025 adjusted EPS guidance range that incorporates the expected deleveraging benefit from reduced interest expense.

Step 3: You respond as you would in the actual interview. The system scores your answer on gross-to-net modeling, acquisition accounting, debt management, and generic product financial analysis.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical finance expertise and what needs stronger Medicaid rebate calculation specificity or exclusivity window economics analysis.

Frequently Asked Questions

What is the pharmaceutical gross-to-net gap and why does it matter for Viatris's financial analysis?
The gross-to-net gap represents the difference between a pharmaceutical product's wholesale acquisition cost and the net average selling price the manufacturer receives after mandatory and contractual deductions. For Viatris branded products, gross-to-net deductions include mandatory Medicaid rebates calculated as a percentage of AMP (at least 23.1% of AMP for branded drugs under OBRA '90), voluntary commercial PBM rebates negotiated for formulary access, distributor chargebacks for pharmacy sales at prices below WAC to contract-eligible purchasers, and 340B ceiling price limitations for sales to qualifying covered entity healthcare providers. For products like EpiPen where the pricing history created significant payer pressure and where generic alternatives are available, the gross-to-net gap can be substantial – making net revenue substantially lower than the WAC-based gross revenue that headline pricing discussions might suggest.

What is Medicaid best price and how does it affect Viatris's commercial contracting?
Medicaid best price is the lowest price that a pharmaceutical manufacturer charges any customer for a covered outpatient drug in the US market, with specific exclusions for certain government programs. Under the Medicaid Drug Rebate Program, manufacturers must report AMP and best price to CMS quarterly, and the Medicaid rebate obligation is calculated as the greater of the AMP-based percentage rebate or the difference between AMP and best price. When Viatris's commercial team negotiates a PBM rebate contract that offers a deep net price to a commercial insurer, that commercial net price may become the Medicaid best price if it falls below the previous best price – triggering higher Medicaid rebate obligations across all Medicaid units sold in that quarter. Finance must model the best price impact of commercial contract negotiations before finalizing rebate terms to prevent inadvertent best price resets that create Medicaid liability exceeding the commercial revenue benefit.

How did the Mylan-Upjohn combination create purchase price accounting complexity?
The November 2020 combination of Pfizer's Upjohn division with Mylan N.V. was structured as a Reverse Morris Trust transaction that required Pfizer to spin off Upjohn and merge it with Mylan tax-free. The transaction was treated as a business combination requiring purchase price allocation, identifying and valuing the intangible assets acquired in the combination. Pharmaceutical combination purchase price allocations typically identify product rights (the estimated present value of future cash flows from acquired marketed products), customer relationships, trade names, and in-process research and development as major intangible asset categories. These acquired intangibles are amortized over their estimated useful lives, creating non-cash amortization charges in Viatris's post-combination income statement that reduce GAAP reported earnings without reducing cash generation. Investors typically evaluate pharmaceutical companies on adjusted earnings measures that exclude acquisition-related amortization to assess the underlying cash earnings capacity of the business.

Why did Viatris divest the biosimilar business to Biocon Biologics?
Viatris completed the divestiture of its biosimilar business to Biocon Biologics in November 2022, receiving approximately $3.3 billion including a significant equity stake in Biocon Biologics. The divestiture served Viatris's deleveraging strategy by generating cash proceeds that were applied to debt reduction, reducing the leverage ratio toward Viatris's target range. Beyond the debt reduction benefit, management concluded that maintaining and growing a biosimilar business required continued clinical development investment and commercial infrastructure investment that competed with Viatris's priorities for its complex generics and off-patent branded products portfolio. The divestiture simplified Viatris's business model by exiting a capital-intensive segment whose growth trajectory required investment that the post-combination deleveraging imperative made difficult to prioritize.

How does Viatris manage foreign exchange exposure across 165 countries?
Viatris generates revenue in markets across all major global regions and currency zones, creating translation exposure when local currency revenue is converted to US dollar reported results. The company's manufacturing operations in India, Ireland, Germany, and other countries create some natural hedge against revenue from those regions, but the geographic mismatch between manufacturing cost currency and customer revenue currency creates net FX exposure. Viatris uses a combination of natural hedging through the manufacturing cost structure, financial hedging instruments for large individual currency exposures, and FX-neutral reporting metrics that allow management and investors to evaluate organic performance trends separate from the translation impacts of currency movements that are not reflective of underlying commercial or operational performance.

Also practice

One full session free. No account required. Real, specific feedback.